Patents by Inventor Marsha M. Wheeler

Marsha M. Wheeler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8445240
    Abstract: The disclosure provides isolated nucleic acid molecules derived from the gut of the termite R flavipes, recombinant nucleic acid molecules comprising a vector and an isolated heterologous nucleic acid molecule operably inserted therein, whereby, when transformed into an appropriate host cell system, the heterologous nucleic acid sequence is expressed as a polypeptide having an activity similar to that when expressed in the gut of the termite R. flavipes. The recombinant nucleic acid molecules can comprise more than one heterologous nucleic acid molecule such that more than one polypeptide may be expressed by the host system. The expressed polypeptides may be substantially purified, or used in a substantially unpurified form, to be admixed with a lignocellulose source to be converted to a fermentable product such as a sugar or a mixture of sugars.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: May 21, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michael E. Scharf, Drion G. Boucias, Aurelien Tartar, Monique R. Coy, Xuguo Zhou, Tamer Ibrahim Zaki Salem, Sanjay B. Jadhao, Marsha M. Wheeler
  • Publication number: 20120064580
    Abstract: The disclosure provides isolated nucleic acid molecules derived from the gut of the termite R flavipes, recombinant nucleic acid molecules comprising a vector and an isolated heterologous nucleic acid molecule operably inserted therein, whereby, when transformed into an appropriate host cell system, the heterologous nucleic acid sequence is expressed as a polypeptide having an activity similar to that when expressed in the gut of the termite R. flavipes. The recombinant nucleic acid molecules can comprise more than one heterologous nucleic acid molecule such that more than one polypeptide may be expressed by the host system. The expressed polypeptides may be substantially purified, or used in a substantially unpurified form, to be admixed with a lignocellulose source to be converted to a fermentable product such as a sugar or a mixture of sugars.
    Type: Application
    Filed: March 31, 2010
    Publication date: March 15, 2012
    Inventors: Michael E. Scharf, Drion G. Boucias, Aurelien Tartar, Monique R. Coy, Xuguo Zhou, Tamer Ibrahim Zaki Salem, Sanjay B. Jadhao, Marsha M. Wheeler
  • Patent number: 7968525
    Abstract: Methods, matrix compositions and kits for increasing the mortality of termites (R. flavipes) and interfering with termite development using RNA interference techniques to target cellulase, lignocellulase, hexamerin, broad, farnesoic acid methyl transferase, cytochrome P450 and vitellogenin activity are provided.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: June 28, 2011
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michael E. Scharf, Xuguo Zhou, Faith M. Oi, Marsha M. Wheeler, Matthew R. Tarver, Monique R. Coy
  • Publication number: 20080107619
    Abstract: A method, composition and system for controlling termites wherein single carbohydrate-based compounds are used as both cellulase inhibitors and feeding stimulants. Di-saccharides, cellobioimidazole (CBI), fluoro-methyl cellobiose (FMCB), and mono-saccharides, fluoro-methyl glucose (FMG) and analogs thereof inhibit termite cellulose digestion, which leads to starvation or stimulates termite feeding to cause mortality. CBI, FMCB and FMG were tested against enzyme fractions that represented endogenous (foregut/salivary gland/midgut) and symbiotic (hindgut) termite cellulases in vitro and in vivo. Feeding stimulation by di-saccharides results in greater cellulase inhibitor intake throughout midrange concentrations (1 mM-10 mM), which is associated with significant termite mortality. In contrast, the monosaccharide inhibitor, FMG did not stimulate feeding, but did inhibit feeding at concentrations above 1 mM, causing mortality.
    Type: Application
    Filed: October 18, 2007
    Publication date: May 8, 2008
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Michael E. Scharf, Xuguo Zhou, Faith M. Oi, Marsha M. Wheeler